AstraZeneca Presents New Respiratory Disease Research at ATS Conference
AstraZeneca will present new data on its respiratory disease treatments at the ATS Conference in May 2025, focusing on advancements in asthma and COPD care. The presentations include phase III data and real-world evidence analyses.
Pharmaceutical company AstraZeneca will present new clinical and real-world data from its respiratory disease research portfolio at the American Thoracic Society (ATS) International Conference in San Francisco, May 16-21, 2025. The company is set to present over 75 abstracts, including eight late-breakers, focusing on advancing treatments for asthma, chronic obstructive pulmonary disease (COPD), eosinophilic granulomatosis with polyangiitis (EGPA), and other chronic inflammatory diseases.
The company aims to transform respiratory care with its comprehensive portfolio. Ruud Dobber, Executive Vice President and President, BioPharmaceuticals Business Unit, AstraZeneca, highlighted that asthma and COPD affect hundreds of millions globally, with COPD being the third leading cause of death. "The data we are presenting at ATS focus on important gaps in current care, including improving the approach to asthma rescue medication, reducing cardiopulmonary risk in COPD, and targeting the underlying mechanisms driving a broad range of inflammatory diseases," Dobber stated.
AstraZeneca will showcase data from its inhaled portfolio, advancing science in asthma and COPD for patients not achieving optimal outcomes. Airsupra (albuterol/budesonide) will be presented as an anti-inflammatory rescue treatment potentially superior to albuterol alone, in line with GINA guidelines. An analysis from the BATURA Phase IIIb trial explores the impact of as-needed Airsupra versus albuterol alone in reducing systemic corticosteroid exposure in mild asthma. A post-hoc analysis of the MANDALA Phase III study will examine time to first severe exacerbation and annualized exacerbation rates within the first three months.
Furthermore, Breztri (budesonide/glycopyrrolate/formoterol fumarate, BGF), an inhaled triple therapy, will present new analyses on its effects on cardiopulmonary outcomes and the connection between COPD and asthma. A post-hoc analysis from the ETHOS Phase III study evaluates the number needed to treat (NNT) for Breztri compared to other therapies in COPD patients. The MITOS EROS+CP studies investigate the impact of early Breztri initiation on reducing COPD exacerbations and cardiopulmonary events, as well as its effects in patients with both COPD and asthma.
The company will also present data from its biologics portfolio, including Fasenra (benralizumab) and Tezspire (tezepelumab), which target underlying mechanisms in inflammatory conditions. Fasenra presentations will include data on remission rates and oral corticosteroid reduction in EGPA. A comparison of Fasenra and depemokimab modeling, along with findings on Fasenra's effect on COPD exacerbations in patients with both asthma and COPD, will also be shared.